Cohort Studymoderate evidence
Glucagon-like Peptide-1 Receptor Agonists and Risk for Anterior Ischemic Optic Neuropathy : A Nationwide Cohort Study.
Annals of internal medicine·July 14, 2026·PMID 42441962
Why it mattersClinicians prescribing GLP-1 receptor agonists for type 2 diabetes or obesity need evidence-based guidance on the potential risk of nonarteritic anterior ischemic optic neuropathy, a rare but serious adverse event. This large, active-comparator study provides reassuring absolute risk estimates and highlights the importance of accounting for confounding by indication when interpreting observational safety signals.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled